Viewing nowCombinationNesinamet Sustained Release Tablet 25/1000 mg (Alogliptin, Metformin Hydrochloride)
Metformin Hydrochloride 1000mg · Alogliptin Benzoate 34mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 202302753 · Approved 2023.09.14 · Insurance code 693904000
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication can be used in conjunction with dietary therapy and exercise therapy to improve blood sugar control in patients with type 2 diabetes. The combined action of alogliptin and metformin helps effectively lower blood sugar levels. This allows for smoother blood sugar management for patients. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.
For antidiabetic therapy, the dose of this drug should be adjusted according to efficacy and tolerability, without exceeding the maximum recommended daily doses of each component: 25mg of alogliptin and 2000mg of extended-release metformin hydrochloride. The initial dose of this drug should be determined based on the patient’s current treatment regimen. This drug should be taken once daily, preferably with the evening meal, to reduce gastrointestinal adverse reactions associated with metformin use, and the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 25/1000mg extended-release tablets once daily. Patients taking this drug 12.5/1000mg or 12.5/500mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin The initial dose of this drug is a total daily dose of alogliptin 25mg and metformin hydrochloride 1000mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of 2000mg to reduce gastrointestinal adverse reactions from metformin. 2. Patients treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of alogliptin 25mg and the patient’s current dose of metformin hydrochloride, based on the patient’s current treatment regimen. - For patients who cannot achieve adequate glycemic control with metformin and pioglitazone combination therapy or metformin and insulin combination therapy, the initial dose of this drug is a total daily dose of alogliptin 25mg; the initial dose of metformin hydrochloride should be determined taking into account the patient’s blood glucose level and current dose. When this drug is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if needed. - Substitution for combination therapy with alogliptin and metformin When switching from combination therapy with alogliptin and metformin to this drug, the dose of this drug should correspond to the patient’s current doses of alogliptin and metformin hydrochloride. Patients with Renal Impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment (creatinine clearance ≥60mL/min). In patients with moderate renal impairment (CKD stage 3A) whose creatinine clearance is ≥45mL/min and <60mL/min, and who do not have other conditions that may increase the risk of lactic acidosis, this drug may be used with dose adjustment as follows: - The daily dose of alogliptin is 12.5mg. - The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, and the maximum daily dose is 1000mg. If creatinine clearance falls below 45mL/min, this drug should be discontinued immediately.
This medication can cause severe lactic acidosis or hypoglycemia; therefore, it should not be used, especially in patients with poor kidney function or severe heart disease. Patients who are hypersensitive to alogliptin, metformin, or any component of this medication, or those who have experienced allergic reactions in the past, should not take it. Patients with moderate to severe impairment of kidney function or those with acute heart failure, acute myocardial infarction, or sepsis should not take this medication. If undergoing radiological tests using iodinated contrast agents, this medication should be temporarily discontinued before and after the test, and should be resumed only after confirming normal kidney function. This medication is not suitable for patients with type 1 diabetes, diabetic ketoacidosis, or diabetic pre-coma. Patients with severe infections or those undergoing surgery, or those with moderate to severe trauma may require insulin therapy instead of this medication. If surgical procedures are to be performed, discontinue this medication 48 hours prior to surgery, and resume only after confirming normal kidney function following the surgery. Patients with impaired liver function, those with pulmonary embolism or severe lung disease, those who consume alcohol excessively, or those with dehydration or severe gastrointestinal disorders should use caution when taking this medication. This medication lowers blood sugar levels; therefore, the risk of hypoglycemia may increase when used with other blood sugar-lowering agents, so blood sugar levels should be monitored closely. During treatment, side effects such as diarrhea, nausea, headache, back pain, and infections may occur. If symptoms are severe, consult a doctor. Women who are pregnant or may become pregnant should avoid taking this medication, and breastfeeding women should also avoid it. The elderly should undergo regular kidney function tests due to the potential for decreased kidney function and should be treated with the minimal effective dose. In case of overdose, medical monitoring and treatment are required, as lactic acidosis may occur due to metformin. This medication should be swallowed whole without chewing, breaking, or crushing, and the tablet shell may be excreted in feces, which is normal.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container, preferably at a temperature between 1 and 30 degrees Celsius. This helps maintain the medication's effectiveness and prevents deterioration.
Light yellow oval sustained release film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Alogliptin Benzoate 34mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Alogliptin Benzoate 17mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Alogliptin Benzoate 17mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Celltrion Healthcare Co., Ltd.
Alogliptin Benzoate 17mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Alogliptin Benzoate 17mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Alogliptin Benzoate 17mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationAlogliptin Benzoate 17mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationAlogliptin Benzoate 17mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.